What is the recommended treatment algorithm for influenza, including antiviral selection and dosing for pregnant patients, severe renal impairment, high‑risk individuals, alternatives for oseltamivir contraindication or resistance, and supportive care measures?

Flu Treatment Algorithm

Oseltamivir 75 mg twice daily for 5 days is the first-line antiviral for influenza treatment in adults, with baloxavir as an alternative for high-risk non-severe cases, and treatment should be initiated immediately upon clinical suspicion without waiting for test results. 1, 2

Initial Assessment and Treatment Initiation

Start antiviral therapy empirically based on clinical presentation when influenza is circulating in the community. Do not delay treatment waiting for laboratory confirmation. The ideal window is within 48 hours of symptom onset, but treatment should still be given beyond this timeframe for hospitalized or high-risk patients 3, 4.

Criteria for Antiviral Treatment:

• Acute influenza-like illness with fever >38°C (or inability to mount fever in immunocompromised/elderly)
• Respiratory symptoms
• Known influenza activity in community 3

Antiviral Selection by Clinical Scenario

Standard Adult Dosing (Normal Renal Function)

Oseltamivir (First-line):

• Treatment: 75 mg orally twice daily for 5 days 1, 3
• Can be given with meals to reduce GI side effects 1
• Available as capsules (30,45,75 mg) or oral suspension (6 mg/mL) 1

Zanamivir (Alternative):

• 10 mg (two 5-mg inhalations) twice daily for 5 days 1
• Contraindicated in chronic respiratory disease (asthma, COPD) due to bronchospasm risk 5
• Requires proper inhaler technique with Diskhaler device 1

Baloxavir (Alternative for high-risk non-severe cases):

• 40-80 kg: 40 mg single dose orally
• ≥80 kg: 80 mg single dose orally 1, 2
• Conditionally recommended by WHO 2024 guidelines for high-risk patients 2

Peramivir (IV option):

• 600 mg single IV infusion over 15-30 minutes 1
• Reserved for patients unable to take oral/inhaled medications

Severe Renal Impairment (CrCl 10-30 mL/min)

Critical dosing adjustment required to prevent toxicity while maintaining early therapeutic levels:

• Treatment: 75 mg once daily for 5 days 5, 3
• Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 doses) 5

Important caveat: Current renal dosing recommendations may delay achievement of therapeutic concentrations in the critical first 24 hours. Consider giving standard first dose (75 mg) followed by reduced maintenance dosing, particularly in patients with mild-moderate impairment 6. Therapeutic drug monitoring can optimize dosing if available 6.

Pregnant Patients

Pregnancy is a high-risk condition requiring immediate treatment:

• Oseltamivir 75 mg twice daily for 5 days (preferred) 4
• Zanamivir 10 mg twice daily for 5 days (alternative based on resistance patterns) 4
• Treat presumptively regardless of vaccination status 4
• Do not withhold treatment if >48 hours from symptom onset 4
• Postexposure prophylaxis recommended up to 2 weeks postpartum (including after pregnancy loss) 4

Pediatric Dosing

Weight-based dosing for children ≥12 months:

• <15 kg: 30 mg twice daily
• 15-23 kg: 45 mg twice daily
• 23-40 kg: 60 mg twice daily

• 40 kg: 75 mg twice daily 1

Infants 9-11 months: 3.5 mg/kg/dose twice daily 5

Term infants 0-8 months: 3 mg/kg/dose twice daily 5

Preterm infants (use postmenstrual age = gestational age + chronological age):

• <38 weeks PMA: 1.0 mg/kg twice daily
• 38-40 weeks PMA: 1.5 mg/kg twice daily

• 40 weeks PMA: 3.0 mg/kg twice daily 5, 1

• Consult pediatric infectious disease for extremely preterm (<28 weeks) 5, 1

Large Body Mass Patients

Standard dosing may be inadequate for patients with obesity. Consider:

• First dose: 75 mg (or proportionately higher based on body mass)
• Therapeutic drug monitoring if available to optimize subsequent doses 6

High-Risk Individuals Requiring Treatment

Treat immediately without waiting for test results if any of the following:

• Age <2 years or ≥65 years
• Pregnancy or ≤2 weeks postpartum
• Chronic pulmonary, cardiovascular, renal, hepatic, neurological, hematologic, or metabolic disorders
• Immunosuppression (including HIV, transplant recipients, chemotherapy)
• Residents of nursing homes or chronic care facilities
• Morbid obesity (BMI ≥40)
• Hospitalized patients with severe illness 1, 7, 2

Oseltamivir Resistance or Contraindication

If oseltamivir resistance documented or contraindicated:

1. Zanamivir (if no respiratory disease): 10 mg twice daily for 5 days 5, 1
2. Baloxavir: Weight-based single dose 1, 2
3. Peramivir IV: 600 mg single dose 1

Monitor local resistance patterns: During 2014-2015 season, only 1.6% of H1N1 viruses were oseltamivir-resistant, while all H3N2 and influenza B remained sensitive 5. Amantadine and rimantadine should NOT be used due to high resistance rates 5.

Supportive Care Measures

Hospitalized Patients - Monitoring Parameters:

Monitor at least twice daily (more frequently if severe):

• Temperature, respiratory rate, pulse, blood pressure
• Mental status
• Oxygen saturation and inspired oxygen concentration
• Early Warning Score system 3

Respiratory Support:

• Supplemental oxygen to maintain SpO2 >90%
• Non-invasive ventilation may bridge to intubation when ICU beds limited (use with appropriate infection control) 3
• Standard lung-protective ventilation strategies for ARDS 8

Additional Supportive Measures:

• Assess for volume depletion; provide IV fluids as needed 3
• Nutritional support in severe/prolonged illness 3
• Monitor for cardiac complications 3

Antibiotics - Use Judiciously:

Do NOT routinely prescribe antibiotics for uncomplicated influenza 3, 2

Consider antibiotics if:

• Recrudescent fever or increasing dyspnea after initial improvement
• High-risk patients with lower respiratory features
• Radiographic pneumonia
• Evidence of bacterial co-infection 3

Antibiotic choices for secondary bacterial pneumonia:

• Non-severe: Co-amoxiclav or tetracycline orally 3
• Severe: IV co-amoxiclav + macrolide (clarithromycin/erythromycin) OR fluoroquinolone (levofloxacin/moxifloxacin) active against S. pneumoniae and S. aureus 3

Avoid These Interventions:

• Corticosteroids (unless other indication): Associated with increased mortality 2, 8, 9
• NSAIDs, mTOR inhibitors, convalescent plasma: Not recommended by WHO 2024 guidelines 2, 9

Chemoprophylaxis Indications

Postexposure prophylaxis (start within 48 hours of exposure):

• Very high-risk individuals (severely immunocompromised, transplant recipients) after household exposure 7
• Unvaccinated household contacts of very high-risk persons 7
• Healthcare personnel during outbreaks 7

Dosing for prophylaxis:

• Oseltamivir: 75 mg once daily for 7 days (community) or 14+ days (institutional outbreak) 1, 7
• Zanamivir: 10 mg once daily for 7 days 1

Do not use prophylaxis as substitute for vaccination 2, 10

Discharge Criteria

Patient should NOT be discharged if ≥2 of the following present:

• Temperature >37.8°C
• Heart rate >100/min
• Respiratory rate >24/min
• Systolic BP <90 mmHg
• Oxygen saturation <90%
• Inability to maintain oral intake
• Abnormal mental status 3

Common Pitfalls to Avoid

1. Delaying treatment for test results - Treat empirically when influenza circulating 3, 4
2. Withholding antivirals beyond 48 hours - Still beneficial in hospitalized/high-risk patients 3, 4
3. Under-dosing in renal impairment - First dose should achieve therapeutic levels quickly 6
4. Using zanamivir in asthmatics - High bronchospasm risk 5, 1
5. Prescribing antibiotics for uncomplicated influenza - Increases resistance without benefit 3, 2
6. Using corticosteroids routinely - Associated with worse outcomes 2, 8, 9